{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116777","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.946752+00:00","generated_at":"2026-05-30T01:56:50.049880+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast","bullets":["Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.","Oncology tests 137,100 (+54.4%); total tests processed 775,800 (+23.9%).","Net loss narrowed to $31.6M ($0.26/sh) from $109M ($0.95/sh); positive cash flow $34.5M.","2024 guidance raised: revenue $1.61-1.64B, gross margin 58-61%, net cash inflow $50-75M.","Cash $922.3M; all convertible notes redeemed/converted on Oct 11, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116777","json":"https://secwatch.observer/filing/0001104659-24-116777.json","markdown":"https://secwatch.observer/filing/0001104659-24-116777.md","text":"https://secwatch.observer/filing/0001104659-24-116777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924116777/0001104659-24-116777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924116777/tm2427439d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:56:50.049880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}